Get started
Author

Denisa Wilkes

Observed names: D Wilkes, D. Wilkes
ORCID: 0009-0007-3133-5152
Observed ORCID: 0009-0007-3133-5152
OpenAlex ID: A5000824763
An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects
2019 · Andrew W. Harrell, Robert Wilson, et al. · Drug Metabolism and Disposition · 27
PDF
ETD001: A long-acting inhaled ENaC blocker, is well tolerated in humans
2022 · P Russell, K Woodward, et al. · European Respiratory Journal · 3
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants
2024 · Assem el Baghdady, Rocío Lledó‐García, et al. · Clinical Pharmacology in Drug Development · 2
PDF
164 Tolerance of ETD001, a long-acting inhaled epithelial sodium channel blocker, in humans
2022 · P. Russell, K. Woodward, et al. · Journal of Cystic Fibrosis · 2
PDF
ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial
2025 · Paul Russell, Kathy Woodward, et al. · Journal of Cystic Fibrosis · 1
PDF
180 First-in-human study to evaluate safety, tolerability, and pharmacokinetics of GDC-6988 (ETD002), a selective inhaled potentiator of the TMEM16A chloride channel
2022 · P. Russell, N. Lewin-Koh, et al. · Journal of Cystic Fibrosis · 1
PDF
Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants
2022 · Malcolm Boyce, Denisa Wilkes, et al. · International Journal of Clinical Pharmacology and Therapeutics · 1
A first-in-human study evaluating safety, PK, and PD of a novel universal anticoagulant reversal agent, OKL-1111
2026 · Edwin Spaans, Denisa Wilkes, et al. · Blood Vessels Thrombosis & Hemostasis
Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects
2025 · Paul Miller, Daniel Repplinger, et al. · Therapeutic Advances in Respiratory Disease
Late Breaking Abstract - GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma
2025 · Dave Singh, Victoria Szenes, et al. · European Respiratory Journal
Author response for "Randomized, phase 1 studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects"
2025 · Paul Miller, Daniel Repplinger, et al. · Publons reviews and discussion
First in-Human Study with Okl-1111, a Novel Small Molecule Universal Anticoagulant and Platelet Inhibitor Reversal Agent
2024 · Edwin Spaans, Denisa Wilkes, et al. · Blood
PDF
Phase I trial HMR code: 23-503
2024 · Denisa Wilkes, Denisa Wilkes · http://isrctn.com/
Phase I trial HMR code: 22-014
2023 · Denisa Wilkes, Anne Phelan · http://isrctn.com/
Phase 1 trial HMR code: 21-017
2023 · Denisa Wilkes · http://isrctn.com/
WS18.03 ETD001: a long-acting inhaled ENaC blocker iswell tolerated in humans
2022 · P. Russell, K. Woodward, et al. · Journal of Cystic Fibrosis
Phase 1 trial, HMR code: 21-004
2022 · Denisa Wilkes · http://isrctn.com/
Works count: 18
Citation count: 37
H-index: 2
I10-index: 1
Year
Topic
Type